Topical nystatin prophylaxis: a likely viable measure for reducing impact of candidemia in neurosurgical patients with early tracheostomy intubation

Excerpt

Only a few reports have been published on the use of topical antifungal prophylaxis [1‐4]. For this reason we read with interest the paper published by Giglio and colleagues [5] underlining the ability of oral nystatin to reduce fungal colonization in surgical/trauma ICU patients. In our experience, we observed a dramatic increase of candidemia prevalence in neurosurgical ICU patients after implementation of early tracheostomy (from 2.2% to 9.7%). Following an analysis of data collected, we developed the idea that Candida colonization could spread by contiguity from the oropharynx to the trachea and the tracheostomy site. The proximity of the tracheostomy to the central venous catheter (CVC) insertion site could be considered a predisposing factor for the development of candidemia. Therefore, we suggested topical nystatin prophylaxis in order to reduce the incidence of candidemia. From an operative point of view, we have encouraged prophylactic interventions consisting of oral nystatin administration (500,000 IU) along with oral and tracheostomy site brushings four times a day. These measures led to a statistically significant reduction of candidemia during the first 7 months of nystatin use: in detail, while 12 of 124 patients (9.7%) developed at least one laboratory confirmed candidemia during the whole of 2011, no blood cultures were positive for Candida spp. in 59 patients admitted to the ICU during the period from January to July 2012 (P = 0.01; Figure 1).

…